"Three Keys To Delaying And Preventing Diabetic Retinopathy" - John M. Aligan, MD and Ronald C. Gentile, MD
John Aljian, MD, associate clinical professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and Ronald Gentile, MD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and director of ocular trauma service at the New York Eye and Ear Infirmary of Mount Sinai, discuss the importance of systemic control in the management of diabetic retinopathy. “It amazes me that many patients have no idea what their hemoglobin AC1 is. They are on antiglycemic medications, even insulin, and have never even heard of it, or forgotten it, or just don’t feel that it’s an important number in their lives,” said Dr. Aljian. Dr. Gentile added, “It’s important that you bring this up. If doctors bring this up to their patients, I think they’ll have a better understanding of what that number actually means and how they can get it lower to prevent them from developing retinopathy and going blind.”
- John M. Aljian, MD, Associate Clinical Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai
- Ronald C. Gentile, MD, Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Director, Ocular Trauma Service, New York Eye and Ear Infirmary of Mount Sinai